Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rs-9-Aminocamptothecin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 18/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | RECQL | P46063 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.82 |
| ▸ | GLA | P06280 | 3/20 | 0.82 |
| ▸ | MEN1 | O00255 | 2/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.82 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.77 |
| ▸ | HTT | P42858 | 2/20 | 0.77 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.77 |
| ▸ | ACHE | P22303 | 1/20 | 0.77 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.77 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.77 |
| ▸ | TP53 | P04637 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 9-Aminocamptothecin SCHEMBL29369669 | 1.00 | TOP1 (1.00) | TOP1KDM4ERECQLTDP1RAB9A | |
| 9-Aminocamptothecin SCHEMBL26578 | 1.00 | TOP1 (1.00) | TOP1KDM4ERECQLTDP1RAB9A | |
| Rs-9-Aminocamptothecin SCHEMBL27705522 | 0.96 | TOP1 (0.92) | TOP1KDM4ERECQLTDP1RAB9A | |
| SCHEMBL25932523 | 0.92 | TOP1 (0.84) | TOP1KDM4ERECQLTDP1RAB9A | |
| SCHEMBL1006662 | 0.91 | TOP1 (1.00) | TOP1KDM4ERECQLTDP1RAB9A | |
| SCHEMBL27561956 | 0.91 | TOP1 (1.00) | TOP1KDM4ERECQLTDP1RAB9A | |
| SCHEMBL23270615 | 0.90 | TOP1 (1.00) | TOP1KDM4ERECQLTDP1RAB9A | |
| SCHEMBL1062768 | 0.90 | TOP1 (1.00) | TOP1KDM4ERECQLTDP1RAB9A | |
| SCHEMBL29664993 | 0.90 | TOP1 (1.00) | TOP1KDM4ERECQLTDP1RAB9A | |
| SCHEMBL1301708 | 0.90 | TOP1 (1.00) | TOP1KDM4ERECQLTDP1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118076428-A | Preparation system and preparation method for producing nano particles | 上海弼领生物技术有限公司 | 2024-05-24 | — | — | CN | claimed |
| CN-117500528-A | Linker and conjugate thereof | 北京海步医药科技有限公司 | 2024-02-02 | — | — | CN | claimed |
| CN-114007737-B | Antibody drug conjugate purification | 默克专利股份公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-118267469-A | Combined pharmaceutical composition for treating driving gene positive lung cancer | 正大天晴药业集团南京顺欣制药有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-118267468-A | Combined pharmaceutical composition for treating tumors | 正大天晴药业集团股份有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-118159300-A | Antibody, drug conjugate and application thereof | 苏州信诺维医药科技股份有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-117916268-A | Novel antibody sequences for diagnosis and therapy | 伊麦吉纳博公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-113347996-B | Combined pharmaceutical composition for treating tumors | 正大天晴药业集团股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-117561330-A | Compositions and methods for generating gamma-delta T cells from induced pluripotent stem cells | 世纪治疗股份有限公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-117479952-A | Combined artificial cell death/reporter polypeptides for chimeric antigen receptor cells and uses thereof | 世纪治疗股份有限公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-117441010-A | Compositions and methods for producing alpha-beta T cells from induced pluripotent stem cells | 世纪治疗股份有限公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-1301966-C | 2-amino-2-alkyl-5-heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors | PHARMACIA CORP (US) | 2007-02-28 | — | — | CN | disclosed |
| CN-1680381-A | Preparation of S-tricyctic lactone | JIANGSU PHARMACEUTICAL INST (CN) | 2005-10-12 | — | — | CN | disclosed |
| CN-1474805-A | 2-amino-2-alkyl-5-heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors | — | 2004-02-11 | — | — | CN | disclosed |
| CN-1101818-C | Novel water-soluble C-ring analogues of 20(s)-camptothecin | REDDY RESEARCH FOUNDATION (IN) | 2003-02-19 | — | — | CN | disclosed |
| CN-1245423-A | Formulation and method for treating neoplasms by inhalation | BATTELLE MEMORIAL INSTITUTE (US) | 2000-02-23 | — | — | CN | disclosed |
| CN-1198164-A | Novel water-soluble C-ring analogues of 20 -camptothecin | REDDY RESEARCH FOUNDATION (IN) | 1998-11-04 | — | — | CN | disclosed |
| EP-0828743-A4 | WATER SOLUBLE CAMPTOTHECIN ANALOGS | SMITHKLINE BEECHAM CORP (US) | 1998-09-02 | — | — | EP | disclosed |
| EP-0828743-A1 | WATER SOLUBLE CAMPTOTHECIN ANALOGS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-03-18 | — | — | EP | disclosed |
| WO-1996038449-A1 | WATER SOLUBLE CAMPTOTHECIN ANALOGS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-12-05 | — | — | WO | disclosed |